Status:
NOT_YET_RECRUITING
Pembrolizumab in First-Line Treatment of Advanced-Stage Classical Hodgkin Lymphoma
Lead Sponsor:
University of Cologne
Conditions:
Hodgkin Lymphoma
Eligibility:
All Genders
18-60 years
Phase:
PHASE2
Brief Summary
The primary objective of this trial is to estimate efficacy of the novel regimen. The primary endpoint is the 1-year PFS rate after treatment with one dose of pembrolizumab followed by four to six cyc...
Eligibility Criteria
Inclusion
- Main
- age 18-60
- advanced stage classical Hodgkin Lymphoma
- no previous treatment for cHL
- Main
Exclusion
- Nodular lymphocyte-predominant Hodgkin lymphoma or composite lymphoma
- Chemotherapy or radiotherapy in medical history
- Prior or concurrent disease that prevents treatment according to protocol
Key Trial Info
Start Date :
August 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2029
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT06045195
Start Date
August 1 2025
End Date
January 1 2029
Last Update
April 6 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
1st Department of Medicine, Cologne University Hospital
Cologne, Germany